We are live on ! Find out more
MU

Mirova US Portfolio holdings

AUM $8.81B
1-Year Est. Return 21.38%
This Fund
S&P 500
This Quarter Est. Return
+11.86%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
AUM
$2.29B
AUM Growth
+$546M
Cap. Flow
+$349M
Cap. Flow %
15.21%
Top 10 Hldgs %
72.22%
Holding
26
New
Increased
19
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
ECL icon
Ecolab
ECL
+$71.2M
2
MSFT icon
Microsoft
MSFT
+$38.5M
3
SBNY
Signature Bank
SBNY
+$38.2M
4
MA icon
Mastercard
MA
+$36.4M
5
EBAY icon
eBay
EBAY
+$34M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$29.7M
2
NVDA icon
NVIDIA
NVDA
+$4.99M
3
DHR icon
Danaher
DHR
+$3.2M
4
ORA icon
Ormat Technologies
ORA
+$1.41M
5
XYL icon
Xylem
XYL
+$1.16M

Sector Composition

Rank Sector Weight
1 Technology 27.9%
2 Financials 19.51%
3 Healthcare 16.46%
4 Consumer Discretionary 10.92%
5 Materials 8.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GILD icon
26
Gilead Sciences
GILD
$167B
-469,932
Closed -$29.7M

Similar funds

Mirova US's Q4 2020 Portfolio in Review

As of Q4 2020, Mirova US held 26 positions worth $2.29B, up 31% from $1.75B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Mirova US deployed $349M of net new capital in Q4 2020, adding to 19 existing holdings.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was NVIDIA, an estimated $4.99M trimmed.

  • Mirova US added most to Ecolab in Q4 2020, an estimated $71.2M increase.
  • Mirova US's biggest Q4 2020 reduction was NVIDIA, cutting an estimated $4.99M.
  • Mirova US fully exited Gilead Sciences in Q4 2020, selling an estimated $29.7M.
  • Mirova US's ten largest holdings make up 72% of its $2.29B portfolio in Q4 2020.
  • Mirova US opened 0 new positions and closed 1 in Q4 2020.
  • Mirova US's portfolio value rose 31% quarter-over-quarter to $2.29B.

Based on Mirova US's 13F filing for Q4 2020, filed 16 Feb 2021.